rs150382575
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_021957.4(GYS2):c.574C>T(p.Arg192Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000465 in 1,613,550 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R192R) has been classified as Benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_021957.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GYS2 | NM_021957.4 | c.574C>T | p.Arg192Ter | stop_gained | 4/16 | ENST00000261195.3 | |
GYS2 | XM_024448960.2 | c.574C>T | p.Arg192Ter | stop_gained | 4/17 | ||
GYS2 | XM_006719063.4 | c.343C>T | p.Arg115Ter | stop_gained | 3/15 | ||
GYS2 | XM_017019245.3 | c.574C>T | p.Arg192Ter | stop_gained | 4/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GYS2 | ENST00000261195.3 | c.574C>T | p.Arg192Ter | stop_gained | 4/16 | 1 | NM_021957.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000329 AC: 5AN: 152098Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000518 AC: 13AN: 251200Hom.: 0 AF XY: 0.0000663 AC XY: 9AN XY: 135770
GnomAD4 exome AF: 0.0000479 AC: 70AN: 1461334Hom.: 0 Cov.: 31 AF XY: 0.0000591 AC XY: 43AN XY: 726988
GnomAD4 genome ? AF: 0.0000328 AC: 5AN: 152216Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74420
ClinVar
Submissions by phenotype
Glycogen storage disorder due to hepatic glycogen synthase deficiency Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 17, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jul 30, 2022 | This sequence change creates a premature translational stop signal (p.Arg192*) in the GYS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GYS2 are known to be pathogenic (PMID: 9691087). This variant is present in population databases (rs150382575, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with GYS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 214530). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 11, 2022 | - - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 31, 2018 | The R192X variant in the GYS2 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R192X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret R192X as a likely pathogenic variant. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at